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Abstract
Background: Optimum management of dyspepsia in primary care is a debatable subject. Testing
for Helicobacter pylori (HP) has been recommended in primary care as this strategy will cure most
underlying peptic ulcer disease and prevent future gastro duodenal disease.
Methods:  A total of 98 patients completed Modified Glasgow Dyspepsia Severity Score
Questionnaire (MGDSSQ) at initial presentation before undergoing the 13Carbon Urea Breath Test
(UBT) for HP. Those with positive UBT received Eradication Therapy with oral Omeprazole 20 mg
twice daily, Clarithromycin 500 mg daily and Amoxycillin 500 mg twice daily for one week followed
by Omeprazole to be completed for another 4 to 6 weeks. Those with negative UBT received
empirical treatment with oral Omeprazole 20 mg twice daily for 4 to 6 weeks. Patients were
assessed again using the MGDSSQ at the completion of treatment and one month after stopping
treatment.
Results: The prevalence of dyspepsia at Universiti Kebangsaan Malaysia-Primary Care Centre was
1.12% (124/11037), out of which 23.5% (23/98) was due to HP. Post treatment assessment in both
HP (95.7%, 22/23) and non HP-related dyspepsia (86.7%, 65/75) groups showed complete or almost
complete resolution of dyspepsia. Only about 4.3% (1/23) in the HP related dyspepsia and 13.3%
(10/75) in the non HP group required endoscopy.
Conclusion: The prevalence of dyspepsia due to HP in this primary care centre was 23.5%.
Detection of HP related dyspepsia yielded good treatment outcomes (95.7%).
Background
Dyspepsia is described as chronic or recurrent pain or dis-
comfort in the upper abdomen. The prevalence of dyspep-
sia in western countries is approximately 25% which
accounts for 2–5% of primary care consultations [1,2].
One of the challenges in treating dyspepsia for primary
care physicians is to determine the optimal treatment for
the patient presenting with new onset or previously unin-
vestigated dyspeptic symptoms [3].
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Dyspepsia could be due to several causes such as peptic
ulcer disease, reflux disease, drugs (especially Non-Steroi-
dal Anti-Inflammatory Drugs, NSAIDs) and idiopathic.
Symptoms commonly overlap, making diagnosis diffi-
cult. Gastro-oesophageal reflux disease (GORD) presents
with predominant or frequent (more than once a week)
heartburn or acid regurgitation [4]. Hence, it is often dif-
ficult to distinguish between dyspepsia and GORD in the
uninvestigated patient who presents with upper gastroin-
testinal symptoms in primary care.
Almost one third of patients presenting with dyspepsia in
primary care have peptic ulcer disease. In patients under-
going endoscopy for peptic ulcer disease, detection and
eradication of Helicobacter pylori (HP) has demonstrated
a potential cure for patients presenting with dyspepsia.
Kurata and colleagues in their study noted that there is a
significantly higher prevalence of peptic ulcer disease in
dyspeptic patients who test positive for HP compared to
those who do not [5]. Early endoscopy may be theoreti-
cally desirable for all patients but this is currently not
practical [2]. Moreover, it is an invasive procedure, costly
and causes discomfort to the patient.
Immediate referral for endoscopy is recommended for
patients on regular NSAIDs and those with alarm symp-
toms such as weight loss, bleeding, anaemia, dysphagia,
jaundice and palpable mass [6]. The recommendation of
endoscopy in older patients is made because of concerns
over the risk of underlying malignancy with increasing age
[7].
To date, the main options for the treatment of younger
patients with uninvestigated dyspepsia without alarming
features include the following [7]:
(1) Empirical H2-receptor antagonist therapy;
(2) Empirical proton pump inhibitor (PPI) therapy
(3) HP testing and treatment of positive cases (HP test
and treat) followed by acid suppression if the patient
remains symptomatic
(4) Early endoscopy alone
(5) Early endoscopy with biopsy for HP and treatment
if positive
(6) Acid suppression followed by endoscopy and
biopsy if the patient returns symptomatic; or
(7) HP test and treat with endoscopy if the patient
remains symptomatic
The Maastricht 2–2000 guidelines and primary care guide-
lines for the management of HP infection recommend a
test-and-treat approach without endoscopy for adult
patients under 45 years presenting in primary care with
persistent dyspepsia [8,9].
However, there is much more limited evidence on the test
and treat approach in Malaysia.
The United States National Institutes of Health (NIH)
[10] recommends the carbon labelled urea breath test
(UBT) as the best diagnostic approach because of its
intrinsic operational advantages. Sensitivities of greater
than 90% and specificities approaching 100% [10] make
UBT the gold standard for diagnosis of active HP disease
[8,11]. To prevent a false negative result, the UBT should
not be administered within four weeks of proton pump
inhibitor (PPI), bismuth or antibiotic therapy [12].
However, the test and treat approach is not currently prac-
tised at primary care level in Malaysia. Apart from private
diagnostic laboratories, only Universiti Kebangsaan
Malaysia Medical Centre (UKMMC) has this facility. This
test is not available in any of the government-funded hos-
pitals across Malaysia.
The management of dyspepsia is an important issue for
both primary care physicians and specialists as the initial
approach may dictate both patient outcome and future
consumption of health care resources. This study aims to
determine the prevalence of HP related dyspepsia and
treatment outcomes among patients attending the UKM
Primary Care Centre, a university funded primary care
clinic. The extension of this service to the primary care
facility from the UKMMC will facilitate the initiation of
eradication at primary care level, hence limiting endos-
copy for cases resistant to treatment. The study also aims
to demonstrate the improvement of symptoms of dyspep-
sia in both groups of HP positive and negative patients
after appropriate treatment.
Methods
This cross-sectional study was conducted at UKM Primary
Care Centre, a teaching primary care centre located in an
urban area south of Kuala Lumpur. The study was con-
ducted over a period of six months (January to June
2005). All new and 'follow-up' patients who attended
UKM Primary Care Centre during the study period were
screened for symptoms suggestive of dyspepsia and subse-
quently managed by the research team. Patients who were
18 to 50 years old and had symptoms of dyspepsia for at
least four weeks were included in the study. Those
excluded from the study were patients who had associated
alarm symptoms (i.e. anaemia, dysphagia, gastrointesti-
nal bleeding, jaundice, lymphadenopathy, palpable mass,Asia Pacific Family Medicine 2009, 8:4 http://www.apfmj.com/content/8/1/4
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significant weight loss), patients on NSAIDs, anticoagu-
lant and steroid drugs, patients previously diagnosed, or
had undergone surgery for gastroenterological or hepato-
biliary disease, patients previously on eradication regimes
for HP infection, patients with previously positive finding
on endoscopy for other gastric pathologies, patients with
family history of gastric cancer and patients who were
pregnant.
The nature of the dyspepsia was assessed by determining
the most predominant symptoms experienced by the
patients. This involved a researcher interviewing the
patients and asking them what they considered to be their
most troublesome and frequent symptoms (i.e. epigastric
pain, bloating, nausea, burping/belching, heartburn, sour
taste or halitosis). The patients were then asked to fill a
self-administered questionnaire regarding severity of dys-
peptic symptoms using the Modified or Abbreviated Glas-
gow Dyspepsia Severity Score. Patients with language
problems were referred to either a researcher or the para-
medical staff who were pre-trained for the period of study.
The patients were then subjected to Urea Breath Test
(GRAF Medical System) using 13 carbon urea following
the method described in the UBT study tool. Specimens
were sent for analysis as soon as possible or not more than
one week. Patients were reviewed and informed about the
result and if the breath test result was positive, the patients
received a regime of: oral Omeprazole 20 mg twice daily,
Amoxycillin 500 mg twice daily & Clarithromycin 500 mg
daily for one week
This regime was chosen as it has been proven to achieve
consistent eradication of rates greater than 90%. (Based
on Malaysian Academy of Medicine Consensus on Man-
agement of Peptic Ulcer Disease [13])
Instruments
Modified Glasgow Dyspepsia Severity Score
This tool consists of an abbreviated version of the original
Glasgow Dyspepsia Severity Dyspepsia Score [14], which
has been shown to be a valid, responsive and reproducible
means of assessing the severity of dyspepsia to allow
measurement of symptoms over a one-month period.
13 Carbon Urea Breath Test (UBT)
A period of fasting before the test was not mandatory but
timing in relation to the last meal was at least two hours
before testing. Ingestion of carbonated drinks before the
procedure was not allowed. Patients were instructed to
take a deep breath and to count from 1 to 5 while blowing
into the chamber bag slowly. Patients were given a drink
containing the substrate (75 mg IRIS 13carbon urea, GRAF
Medical Systems) and orange juice in a 3/4 glass of water.
The patients were instructed to blow at indicated time
intervals (10, 20, 30 minutes) into the respective cham-
bers. The filled chambers were transported for analysis
either immediately or within one week. UBT positive indi-
cates HP-related dyspepsia while UBT negative indicates
Non-HP-related dyspepsia
Ethical approval
This study obtained ethical approval from the Medical
Research Center, Faculty of Medicine, Universiti Kebang-
saan Malaysia (#FF-179-2004).
Data analysis
The data was analyzed using SPSS™ (Statistical Program
for Social Sciences) software program version 11.5. Pear-
son's Chi square was used for detection of differences in
categorical variables between the two groups (HP and
Non HP). Mann Whitney's test was used for analysis of
non-normally distributed data. The paired t-test was used
to assess the mean scores pre and post treatment. The
unpaired t -test used to assess the relation between quan-
titative and qualitative variables. All tests were done using
a priori level of significance of 0.05.
Sample size
Using the Epidinfo® programme and a prevalence range of
30 to 40% at 95% confidence interval, the calculated sam-
ple size required was 92 patients.
Results
Over the six month period of the study, a total of 124
patients presented with dyspepsia, making the prevalence
of dyspepsia in adult patients attending PPP-HUKM
1.12% (124/11037). Further analysis on dyspeptic partic-
ipants (98/124) recruited into this study, 23.5% (23/98)
tested positive for urea breath test (HP-related dyspepsia)
and 76.5% (75/98) tested negative for urea breath test
(Non HP-related dyspepsia).
Both the HP and non HP-related dyspepsia groups
showed statistically significant decline in the post treat-
ment scores following treatment with eradication and
empirical therapy respectively. (Table 1)
Post eradication assessment of those with HP-related dys-
pepsia demonstrated 95.7% (22/23) complete or almost
complete resolution of dyspepsia symptoms (score 0–1),
whereas only 1 (4.3%) continued to experience dyspepsia
(score more than 1). In the Non HP- related dyspepsia
group, 13.3% (10/75) did not respond to treatment, with
a mean score of 4.5. There were a higher proportion of
patients in the non-HP group who required further endos-
copy compared with the HP-related dyspepsia group
(13.3% vs. 4.3%). (Table 2)Asia Pacific Family Medicine 2009, 8:4 http://www.apfmj.com/content/8/1/4
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Discussion
Since HP was first cultured by Warren and Marshall in
1983, much has been learned about its clinical aspects
and its epidemiology. Knowledge of the epidemiology of
this infection comes mainly from prevalence studies.
Investigation of the incidence of HP infection has been
limited due to difficulties in identifying the case at the
onset. In general HP infection is more frequent in devel-
oping countries than in developed nations. In developed
countries, HP infection is acquired at fairly constant rate
of 2–6% per year with prevalence 20–40% in adults [15].
Malaysian data shows that the prevalence of HP infection
varies widely from 11 to 70% with an average of 35 to
40%. The highest rate were seen among the indigenous
natives (54 to 65.3%) in east coast of Sabah, East Malaysia
[16].
The overall prevalence of HP- related dyspepsia below the
age of 50 years old found in this study was 22.5% (23/98).
This is at the lower end of the range in the study by KL
Goh where the overall prevalence of HP ranged from 26.4
to 55.0% in various parts of Malaysia, covering the Penin-
sular as well as East Malaysia [16].
The decline in the prevalence of HP infection seen in this
study may reflect the steady improvement of our socioe-
conomic conditions resulting in decreased transmission
as living conditions and hygiene improved [16]. Moreo-
ver, the setting for this study was done in an urban based
primary care clinic with the majority of the population
from the lower to upper middle income groups.
Our study also recorded the individual's predominant
symptom to ensure that definition of dyspepsia, (which is
pain or discomfort at centre upper abdomen), is strictly
followed and to exclude patients who presented with
heartburn (gastro-oesophageal reflux disease, GORD) as a
predominant symptom.
This study has shown that the treatment response was
good with most of the respondents achieved complete or
almost complete resolution of dyspepsia symptoms. The
use of symptomatic response to HP eradication therapy as
a marker of post treatment status has been evaluated by
McColl (1998) who concluded that complete resolution
of dyspeptic symptoms is a powerful predictor of eradica-
tion of HP infection in ulcer patients. However, persist-
ence of symptoms is a weak predictor of persisting
infection; hence patients with persisting dyspepsia must
have their HP status rechecked to guide further manage-
ment [14]. This was supported in this study by the endos-
copy findings of the participants who were referred for
persistent symptoms. Eleven (11.2%) of them were
referred; 10 (13.3%) were from the non HP-related dys-
pepsia group and only one (3.3%) from the HP-related
dyspepsia group. Four of them did not turn up and the
results of the other seven were traced.
Post treatment review of the HP and non HP related dys-
peptic patients who had persistent symptoms, tissue biop-
sies taken via endoscopy tested negative for HP infection.
Persistence of symptoms was found to be due to pan gas-
tritis, reflux oesophagitis and mild gastritis.
Our study showed that a small number of patients
required referral for endoscopy (1/23, 4.3%) when using
the UBT as an initial approach in young patients with dys-
pepsia without alarm symptoms. This was similar to find-
ings of other studies [2,8,10,11].
Although the test and treat strategy showed encouraging
results, we do note that there are limitations to our study.
The results obtained only reflected findings from a single
urban based primary care centre. It does not reflect the
overall population of primary care attendees which are
Table 1: Paired t-test in symptoms score decline pre and post treatment in HP and Non-HP related dyspepsia
Symptom score
Mean (SD)
Group N Pre Treatment Post Treatment Score Decline 95% Confidence Interval
HP 23 8.43 ± 1.56 0.87 ± 1.01 7.57 ± 1.59 6.88 ± 8.25 *
Non HP 75 7.00 ± 1.52 1.05 ± 1.43 5.95 ± 1.92 5.20 ± 6.39 †
*p = 0.0008, †p = 0.0008
Table 2: Treatment outcomes in patients presenting with 
dyspepsia
ENDOSCOPY
No Yes
HP 95.7% (22/23) 4.3% (1/23)
Non HP 86.7% (65/75) 3.3% (10/75)
Total 88.8% (87/98) 11.2% (11/98)Publish with BioMed Central    and   every 
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largely based in the suburban and rural areas. Further
multicentred studies looking into the cost effectiveness of
testing for HP using the UBT should be done.
Conclusion
Based on this study, the prevalence of HP related dyspep-
sia among adult patients attending a primary care centre is
23.5% using the UBT. The treatment response using erad-
ication regime (with Omeprazole, Calrithromycin and
Amoxycillin for one week) showed encouraging response
with only 4.3% (1/23) requiring endoscopy.
UBT should be an option for detection of HP related dys-
pepsia in primary care setting based on its non invasive,
high patient acceptance and highly sensitive features.
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